SCHEMBL168006

SCHEMBL168006

CN(C)CNC(=O)c1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.61
LMNA P02545 1/20 0.55
POLB P06746 1/20 0.55
HPGD P15428 2/20 0.51
HDAC1 Q13547 2/20 0.51
HDAC6 Q9UBN7 2/20 0.51
ALDH1A1 P00352 1/20 0.51
NAAA Q02083 1/20 0.51
HDAC3 O15379 1/20 0.51
HDAC4 P56524 1/20 0.51
HDAC7 Q8WUI4 1/20 0.51
HDAC2 Q92769 1/20 0.51
HDAC10 Q969S8 1/20 0.51
HDAC11 Q96DB2 1/20 0.51
HDAC8 Q9BY41 1/20 0.51
HDAC9 Q9UKV0 1/20 0.51
HDAC5 Q9UQL6 1/20 0.51
NPC1 O15118 4/20 0.50
RAB9A P51151 4/20 0.50
SMN1; SMN2 Q16637 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14823336 0.86 GAA (0.59) GAALMNAPOLBHPGDHDAC1
SCHEMBL29016424 0.85 GAA (0.57) GAALMNAPOLBHPGDHDAC1
SCHEMBL3884172 0.83 GAA (0.55) GAALMNAPOLBHPGDHDAC1
SCHEMBL28683590 0.83 GAA (0.55) GAALMNAPOLBHPGDHDAC1
SCHEMBL3195736 0.82 GAA (0.53) GAALMNAPOLBHPGDHDAC1
SCHEMBL2087431 0.81 ALDH1A1 (0.62) GAALMNAPOLBHPGDHDAC1
SCHEMBL9231802 0.81 KDM4E (0.55) GAALMNAALDH1A1NAAANPC1
Hydrochloric Acid SCHEMBL20547794 0.79 ALDH1A1 (0.60) GAALMNAPOLBHPGDHDAC1
SCHEMBL9274479 0.79 THRB (0.66) GAALMNAHDAC1HDAC6ALDH1A1
SCHEMBL29336411 0.79 KMT2A (0.50) GAALMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104418822-B Compound with xanthine oxidase inhibitory activity and application thereof 南京华威医药科技开发有限公司 2016-12-28 CN disclosed
US-9475783-B2 Antimicrobial agents RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2016-10-25 US disclosed
US-20150031694-A1 ANTIMICROBIAL AGENTS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2015-01-29 US disclosed
EP-2828245-A1 ANTIMICROBIAL AGENTS Rutgers, The State University of New Jersey (US) 2015-01-28 EP disclosed
WO-2014060112-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 WO disclosed
WO-2014060113-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 WO disclosed
WO-2013142712-A1 ANTIMICROBIAL AGENTS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2013-09-26 WO disclosed
US-8501782-B2 Piperidinyl derivatives as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2013-08-06 US disclosed
US-8501782-B2 Piperidinyl derivatives as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2013-08-06 US disclosed
EP-2614052-A1 NOVEL PIPERAZINE ANALOGS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS Bristol-Myers Squibb Company (US) 2013-07-17 EP disclosed
US-20090029992-A1 SUBSTITUTED PYRAZOLE COMPOUNDS MIIKANA THERAPEUTICS, INC. 2009-01-29 US disclosed
US-20090029992-A1 SUBSTITUTED PYRAZOLE COMPOUNDS MIIKANA THERAPEUTICS, INC. 2009-01-29 US disclosed
WO-2008115499-A1 MANNICH BASE N-OXIDE DRUGS STATE OF OREGON ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF OREGON (US) 2008-09-25 WO disclosed
US-20070142368-A1 Substituted pyrazole compounds MIIKANA THERAPEUTICS, INC. 2007-06-21 US disclosed
US-20070142368-A1 Substituted pyrazole compounds MIIKANA THERAPEUTICS, INC. 2007-06-21 US disclosed
US-20050261332-A1 Sulfonamides and uses thereof ELIXIR PHARMACEUTICALS, INC. 2005-11-24 US disclosed
EP-0804420-A1 TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS American Cyanamid Company (US) 1997-11-05 EP disclosed
EP-0038541-B1 NOVEL PRODRUGS OF BIOLOGICALLY ACTIVE AGENTS CONTAINING MERCAPTO GROUPS, PROCESS FOR PREPARING AND THERAPEUTICALLY EFFECTIVE COMPOSITION CONTAINING THE SAME MERCK & CO. INC. (US) 1986-08-13 EP disclosed
US-4443435-A ANTICARCINOGENS, HYPOTENSIVE AGENTS, HYPERTHYROIDISM MERCK & CO., INC. (US) 1984-04-17 US disclosed
EP-0038541-A1 Novel prodrugs of biologically active agents containing mercapto groups, process for preparing and therapeutically effective composition containing the same MERCK & CO. INC. (US) 1981-10-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150031694-A1 ANTIMICROBIAL AGENTS CFTR, MRPL21, ABCB11 GAA 2221/4885LMNA 3698/4885POLB 3294/4885
US-20070142368-A1 Substituted pyrazole compounds AURKC, AURKA, AURKB GAA 2410/4885LMNA 2446/4885POLB 1729/4885
US-20050261332-A1 Sulfonamides and uses thereof GLS2, STS, ABAT GAA 54/4885LMNA 1603/4885POLB 2579/4885
US-20090029992-A1 SUBSTITUTED PYRAZOLE COMPOUNDS AURKC, AURKA, AURKB GAA 2410/4885LMNA 2446/4885POLB 1729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.